Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Zai Lab Ltd ADR (NQ: ZLAB ) 30.92 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 30.92 Bid (Size) 28.00 (2) Ask (Size) 36.58 (1) Prev. Close 30.92 Today's Range 30.92 - 30.92 52wk Range 13.48 - 36.60 Shares Outstanding 956,637,360 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China October 29, 2024 From Zai Lab Limited Via Business Wire Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results October 24, 2024 The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells. Via Investor's Business Daily Performance YTD +18.65% +18.65% 1 Month +17.34% +17.34% 3 Month +70.73% +70.73% 6 Month +85.37% +85.37% 1 Year +10.71% +10.71% More News Read More UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday October 24, 2024 Via Benzinga ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer October 24, 2024 From Zai Lab Limited Via Business Wire Zai Lab Announces Participation in November and December Investor Conferences October 18, 2024 From Zai Lab Limited Via Business Wire Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 October 17, 2024 From Zai Lab Limited Via Business Wire Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 October 16, 2024 From Zai Lab Limited Via Business Wire Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 October 09, 2024 From Zai Lab Limited Via Business Wire Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session September 25, 2024 Via Benzinga Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 September 17, 2024 From Zai Lab Limited Via Business Wire Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024 August 27, 2024 From Zai Lab Limited Via Business Wire Zai Lab Announces Participation in September Investor Conferences August 22, 2024 From Zai Lab Limited Via Business Wire Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates August 06, 2024 From Zai Lab Limited Via Business Wire Why Is Zynex (ZYXI) Stock Down 24% Today? July 26, 2024 Via InvestorPlace Topics Earnings Exposures Financial Why Is DexCom (DXCM) Stock Down 38% Today? July 26, 2024 Via InvestorPlace Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem July 26, 2024 Via InvestorPlace Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China July 16, 2024 From Zai Lab Limited Via Business Wire Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy July 15, 2024 From Zai Lab Limited Via Business Wire Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 July 10, 2024 From Zai Lab Limited Via Business Wire Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D June 11, 2024 From Zai Lab Limited Via Business Wire Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 04, 2024 Via Benzinga Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday June 04, 2024 Via Benzinga Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis May 22, 2024 From Zai Lab Limited Via Business Wire Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China May 20, 2024 From Zai Lab Limited Via Business Wire Zai Lab Announces Participation in May and June Investor Conferences May 16, 2024 From Zai Lab Limited Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
